<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25046">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01895114</url>
  </required_header>
  <id_info>
    <org_study_id>010-263</org_study_id>
    <nct_id>NCT01895114</nct_id>
  </id_info>
  <brief_title>Assessment of Renal Function in Cirrhotic Patients</brief_title>
  <official_title>Assessment of Renal Function in Cirrhotic Patients -A Comparison of Cystatin C and Creatinine Based Calculations to 125I-iothalamate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor Research Institute</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study  is to help determine whether cystatin C is a more sensitive
      laboratory measurement for renal function in cirrhotic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Serum cystatin C, creatinine clearance based calculations, and 125I-Iothalamate clearance
      (Glofil) will be obtained in 220 patients with cirrhosis. Utilizing this information, the
      correlation between cystatin C and 125I-Iothalamate clearance will be obtained. In addition,
      the current serum creatinine based calculations and true creatinine clearance will also be
      correlated with 125I-Iothalamate clearance. The results of this study should help to
      determine whether serum cystatin C is a more sensitive laboratory measurement of renal
      function in patients with cirrhosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Creatinine based blood and urine laboratory tests as a measure of renal function in patients with chirrosis of the liver.</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Liver Failure</condition>
  <condition>Renal Failure</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from Baylor All Saints Medical Center and Baylor University Medical Center who
        have cirrhosis and a stable urine creatinine
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  over 18 undergoing evaluation for a liver transplant

        Exclusion Criteria:

          -  known allergy or sensitivity to 125I-Iothalamate
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard Fischbach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor All Saints</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erin Fassett, RN</last_name>
    <phone>817-922-7667</phone>
    <email>Erin.Fassett@baylorhealth.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Baylor All Saint's Medical Center in Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Fassett, RN,MSN,MBA</last_name>
      <phone>214-820-7755</phone>
      <email>Erin.Fassett@baylorhealthe.du</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Acker, RN</last_name>
      <phone>214-820-6624</phone>
      <email>Michelle.Acker@baylorhealth.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 3, 2014</lastchanged_date>
  <firstreceived_date>February 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal function</keyword>
  <keyword>cirrhotic patients</keyword>
  <keyword>transplant evaluation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
